Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial

David Ferry, Lucinda Billingham, Hugh Jarrett, David Dunlop, Penella J Woll, Marianne Nicolson, Riyaz Shah, Joyce Thompson, James Spicer, D Muthukumar, Geraldine Skailes, Pauline Leonard, A D Chetiyawardana, Paula Wells, Conrad Lewanski, Barbara Crosse, Michelle Hill, Piers Gaunt, Kenneth O'Byrne, David Ferry, Lucinda Billingham, Hugh Jarrett, David Dunlop, Penella J Woll, Marianne Nicolson, Riyaz Shah, Joyce Thompson, James Spicer, D Muthukumar, Geraldine Skailes, Pauline Leonard, A D Chetiyawardana, Paula Wells, Conrad Lewanski, Barbara Crosse, Michelle Hill, Piers Gaunt, Kenneth O'Byrne

Abstract

Background: Platinum-based combination chemotherapy is standard treatment for the majority of patients with advanced non-small-cell lung cancer (NSCLC). The trial investigates the importance of the choice of platinum agent and dose of cisplatin in relation to patient outcomes.

Methods: The three-arm randomised phase III trial assigned patients with chemo-naïve stage IIIB/IV NSCLC in a 1:1:1 ratio to receive gemcitabine 1250 mg/m2 on days 1 and 8 of a 3-week cycle with cisplatin 80 mg/m2 (GC80) or cisplatin 50 mg/m2 (GC50) or carboplatin AUC6 (GCb6) for a maximum of four cycles. Primary outcome measure was survival time, aiming to test for a difference between treatment arms and also assess non-inferiority with pre-defined margin selected as hazard ratio (HR) of 1.2. Secondary outcome measures included response rate, adverse events and quality of life (QoL).

Findings: The trial recruited 1363 patients. Survival time differed significantly across the three treatment arms (p = 0.046) with GC50 worst with median 8.2 months compared to 9.5 for GC80 and 10.0 for GCb6. HRs (adjusted) for GC50 compared to GC80 was 1.13 (95% confidence interval [CI] 0.99-1.29) and for GC50 compared to GCb6 was 1.23 (95% CI: 1.08-1.41). GCb6 was significantly non-inferior to GC80 (HR = 0.93, upper limit of one-sided 95% CI 1.04). Adjusting for QoL did not change the findings. Best objective response rates were 29% (GC80), 20% (GC50) and 27% (GCb6), p < 0.007. There were more dose reductions and treatment delays in the GCb6 arm and more adverse events (60% with at least one grade 3-4 compared to 43% GC80 and 30% GC50).

Interpretation: In combination with gemcitabine, carboplatin at AUC6 is not inferior to cisplatin at 80 mg/m2 in terms of survival. Carboplatin was associated with more adverse events and not with better quality of life. Cisplatin at the lower dose of 50 mg/m2 has worse survival which is not compensated by better quality of life. CLINICALTRIALS.

Gov identifier: NCT00112710.

Eudract number: 2004-003868-30.

Cancer research uk trial identifier: CRUK/04/009.

Keywords: Carboplatin; Cisplatin; Gemcitabine; Non-small-cell lung cancer; Quality of life; Randomised phase III trial.

Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.

Figures

Fig. 1
Fig. 1
: Trial profile. aMultiple reasons were recorded and frequencies reporting the top four reasons are given here; bincludes grade 3 or 4 non-haematological or symptomatic grade 4 haematological; cdied within 28 d of day 1 of the last cycle received.
Fig. 2
Fig. 2
(A) Kaplan–Meier survivor functions for each treatment group. (B) Pairwise comparisons of survival showing HRs (adjusted for stage and performance status) with two-sided 95% CIs (solid line) for assessment of difference (compare either end against HR = 1) and one-sided 95% CIs (dashed line) for assessment of non-inferiority (compare upper values against HR = 1.2).
Fig. 3
Fig. 3
Mean EQ-5D utility score over 12 months (represented as a step function joining the means of all patients still alive at each observed death time in the trial).

References

    1. Lozano R., Naghavi M., Foreman K., Lim S., Shibuya K., Aboyans V. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128.
    1. Cancer Research UK, [Accessed December 2016].
    1. Gettinger S., Lynch T. A decade of advances in treatment for advanced non-small cell lung cancer. Clin Chest Med. 2011;32:839–851.
    1. Non-small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Brit Med J. 1995;311:899–909.
    1. NSCLC Meta-Analyses Collaborative Group Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26:4617–4625.
    1. Rudd R.M., Gower N.H., Spiro S.G., Eisen T.G., Harper P.G., Littler J.A. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol. 2005;23:142–153.
    1. Hotta K., Matsuo K., Ueoka H., Kiura K., Tabata M., Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non–small cell lung cancer. J Clin Oncol. 2004;22:3852–3859.
    1. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–98.
    1. Scagliotti G.V., De Marinis F., Rinaldi M., Crino L., Gridelli C., Ricci S. Phase III randomised trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol. 2002;20(21):4285–4291.
    1. Calvert A.H., Newell D.R., Gumbrell L.A., O'Reilly S., Burnell M., Boxall F.E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748–1756.
    1. Rosell R., Gatzemeier U., Betticher D.C., Keppler U., Macha H.N., Pirker R. Phase III randomised trial comparing paclitaxel/carboplatin versus paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol. 2002;13:1539–1549.
    1. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543–3551.
    1. Masters G.A., Temin S., Azzoli C.G., Giaccone G., Baker S., Jr., Brahmer J.R. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33:3488–3515.
    1. Reck M., Popat S., Reinmuth N., De Ruysscher D., Kerr K.M., Peters S., on behalf of the ESMO Guidelines Working Group Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl. 3):iii27–iii39.
    1. Lindsay C.R., Shaw E., Brenton J.D., Butler R., Davies J., de Castro Gonzalez. NCRI cancer conference abstracts. 2015. A national platform for molecular diagnostics: results from phase I of the Cancer Research UK Stratified Medicine Programme.
    1. Reck M., Rodriguez-Abreu D., Robinson A.G., Hui R., Csoszi T., Fulop A., for the KEYNOTE-024 Investigators Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833.
    1. Wright J.G., Boddy A.V., Highlty M., Fenwick J., McGill A., Calvert A.H. Estimation of glomerular filtration rate in cancer patients. Br J Cancer. 2001;84:452–459.
    1. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216.
    1. Cancer Therapy Evaluation Program . 2003. Common terminology criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS March 31. Publish Date: August 9, 2006.
    1. Aaronson N.K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Dues N.J. The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376.
    1. Bergman B., Aaronson N.K., Ahmedzai S., Kaasa S., Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer. 1994;30A:635–642.
    1. The EuroQol group EuroQol—a new facility for the measurement of health related quality of life. Health Policy. 1990;16:199–208.
    1. Kahan B.C., Morris T.P. Improper analysis of trials randomised using stratified blocks or minimisation. Stat Med. 2012;31:328–340.
    1. Morikawa T., Yoshida M. A useful testing strategy in phase III trials: combined test of superiority and test of equivalence. J Biopharm Stat. 1995;5(3):297–306.
    1. Billingham L.J., Abrams K.R. Simultaneous analysis of quality of life and survival data. Stat Methods Med Res. 2002;11:25–48.
    1. Ardizzoni A., Boni L., Tiseo M., Fossella F.V., Schiller J.H., Paesmans M. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99:847–857.
    1. Jiang J., Liang X., Zhou X., Huang R., Chu Z. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer. 2007;57:348–358.
    1. Go R.S., Adjei A.A. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999;17:409–422.
    1. Grunberg S.M., Hesketh P.J. Control of chemotherapy-induced emesis. N Engl J Med. 1993;329:1790–1796.
    1. Schmoll H.J., Van Cutsem E., Stein A., Valentini V., Glimelius B., Haustermans K. ESMO consensus guidelines for management of patients with colon and rectal cancer: a personalised approach to clinical decision making. Ann Oncol. 2012;23:2479–2516.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi